Halyard Health (NYSE:HYH) shares reached a new 52-week high and low during trading on Thursday . The stock traded as low as $60.19 and last traded at $59.85, with a volume of 4110 shares traded. The stock had previously closed at $60.00.

Several research analysts have recently commented on HYH shares. Zacks Investment Research raised Halyard Health from a “hold” rating to a “strong-buy” rating and set a $54.00 price target for the company in a research report on Friday, March 2nd. KeyCorp raised Halyard Health from a “sector weight” rating to an “overweight” rating in a research report on Thursday, April 5th. ValuEngine raised Halyard Health from a “hold” rating to a “buy” rating in a research report on Wednesday, February 28th. Stifel Nicolaus boosted their price target on Halyard Health from $52.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, May 3rd. Finally, Morgan Stanley boosted their price target on Halyard Health from $48.50 to $52.00 and gave the stock an “underweight” rating in a research report on Thursday, May 3rd. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $56.80.

The stock has a market capitalization of $2.77 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 3.75 and a beta of 1.67. The company has a quick ratio of 2.96, a current ratio of 3.22 and a debt-to-equity ratio of 0.43.

Halyard Health (NYSE:HYH) last announced its earnings results on Wednesday, May 2nd. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.59. Halyard Health had a return on equity of 7.90% and a net margin of 7.72%. The company had revenue of $156.40 million for the quarter, compared to analyst estimates of $155.08 million. During the same period in the prior year, the company posted $0.48 EPS. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. equities analysts anticipate that Halyard Health will post 1.77 EPS for the current year.

A number of large investors have recently made changes to their positions in HYH. SG Americas Securities LLC increased its position in Halyard Health by 138.8% during the 4th quarter. SG Americas Securities LLC now owns 25,386 shares of the medical instruments supplier’s stock valued at $1,172,000 after buying an additional 14,757 shares in the last quarter. Mutual of America Capital Management LLC increased its position in Halyard Health by 3.8% during the 4th quarter. Mutual of America Capital Management LLC now owns 39,443 shares of the medical instruments supplier’s stock valued at $1,821,000 after buying an additional 1,462 shares in the last quarter. Aperio Group LLC increased its position in Halyard Health by 5.0% during the 4th quarter. Aperio Group LLC now owns 33,881 shares of the medical instruments supplier’s stock valued at $1,565,000 after buying an additional 1,607 shares in the last quarter. ING Groep NV increased its position in Halyard Health by 23.2% during the 4th quarter. ING Groep NV now owns 7,060 shares of the medical instruments supplier’s stock valued at $326,000 after buying an additional 1,329 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Halyard Health during the 4th quarter valued at about $743,000. 90.46% of the stock is currently owned by institutional investors.

Halyard Health Company Profile

Halyard Health, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.